Biotie: Selincro enters the market in Germany


BIOTIE THERAPIES CORP.          STOCK EXCHANGE RELEASE       29 August 2014 at
9.00 a.m.

Biotie: Selincro enters the market in Germany

Biotie today announced that its partner H.Lundbeck A/S (Lundbeck) has brought
Selincro on the market in Germany. According to the terms of the license
agreement between Biotie and Lundbeck for Selincro, Biotie is eligible for a
milestone payment of EUR 2 million related to the market entry. Lundbeck will
continue the rollout of Selincro in additional European markets during 2014.

Turku, 29 August 2014

Biotie Therapies Corp.

Timo Veromaa
President and CEO

For further information, please contact:

Virve Nurmi, Investor Relations Manager
tel. +358 2 274 8900, e-mail: virve.nurmi@biotie.com

Distribution:
NASDAQ OMX Helsinki Ltd
Main Media

www.biotie.com

About Selincro (nalmefene):

Selincro is indicated for the reduction of alcohol consumption in adult patients
with alcohol dependence who have a high drinking risk level (>60 g/day for men,
>40 g/day for women) without physical withdrawal symptoms and who do not require
immediate detoxification. Selincro should be prescribed in conjunction with
continuous psychosocial support focused on treatment adherence and the reduction
of alcohol consumption. Treatment should be initiated only in patients who
continue to have a high drinking risk level two weeks after an initial
assessment. Selincro is to be taken as-needed; that is, on each day the patient
perceives a risk of drinking alcohol, one tablet should be taken, preferably
1-2 hours prior to the anticipated time of drinking.

Selincro received European marketing authorization in February 2013 and has to
date been introduced in over 20 European markets. Biotie has licensed global
rights to Selincro to Lundbeck. Under the terms of the agreement, Biotie is
eligible for up to EUR 89 million in upfront and milestone payments plus
royalties on sales of Selincro. Upon payment of the milestone for market entry
in Germany, Biotie will have received EUR 20 million of such milestone payments
from Lundbeck. A further payment of EUR 2 million is expected on commercial
launch of Selincro in France with further potential milestone payments on
launches in certain other markets and if the product reaches certain
predetermined sales. In addition, Biotie will continue to receive royalties on
sales in all launched markets and will make a contribution to Lundbeck towards
post approval commitments studies. Lundbeck is responsible for the registration,
manufacturing and marketing of the product.

About Biotie

Biotie is a specialized drug development company focused on products for
neurodegenerative and psychiatric disorders. Biotie's development has delivered
Selincro (nalmefene) for alcohol dependence, which received European marketing
authorization in 2013 and is currently being rolled out across Europe by partner
Lundbeck. The current development products include tozadenant for Parkinson's
disease, which is transitioning into Phase 3 development, and three additional
compounds which are in Phase 2 development for cognitive disorders including
Parkinson's disease dementia, cocaine dependence, and primary sclerosing
cholangitis (PSC), a rare fibrotic disease of the liver.


[HUG#1852050]